Brokers Offer Predictions for Inozyme Pharma, Inc.’s Q1 2025 Earnings (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZY) – Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for Inozyme Pharma in a report released on Tuesday, May 7th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($0.46) per share for the quarter. Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.46) per share.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Tuesday, March 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04).

A number of other research analysts have also issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, March 13th. Finally, Bank of America reduced their target price on shares of Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th.

Inozyme Pharma Stock Up 0.2 %

Inozyme Pharma stock opened at $4.65 on Thursday. The firm has a market capitalization of $287.65 million, a P/E ratio of -3.35 and a beta of 1.54. The company has a current ratio of 13.36, a quick ratio of 13.36 and a debt-to-equity ratio of 0.32. Inozyme Pharma has a twelve month low of $2.69 and a twelve month high of $7.80. The stock’s fifty day simple moving average is $5.59 and its 200-day simple moving average is $4.75.

Hedge Funds Weigh In On Inozyme Pharma

Several hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its position in shares of Inozyme Pharma by 30.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 5,537,500 shares of the company’s stock valued at $23,258,000 after purchasing an additional 1,287,500 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Inozyme Pharma by 346.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 311,880 shares of the company’s stock valued at $1,310,000 after acquiring an additional 242,080 shares during the period. Laurion Capital Management LP grew its position in shares of Inozyme Pharma by 170.5% during the third quarter. Laurion Capital Management LP now owns 677,329 shares of the company’s stock worth $2,845,000 after acquiring an additional 426,961 shares during the last quarter. Eventide Asset Management LLC purchased a new position in shares of Inozyme Pharma during the third quarter worth approximately $13,125,000. Finally, FMR LLC increased its holdings in shares of Inozyme Pharma by 229.2% in the 3rd quarter. FMR LLC now owns 2,465,232 shares of the company’s stock valued at $10,354,000 after acquiring an additional 1,716,398 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the transaction, the chief executive officer now directly owns 20,665 shares of the company’s stock, valued at approximately $143,415.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 11.88% of the stock is owned by corporate insiders.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.